Live
- Kotak Mahindra vows fix after RBI action
- Banks failing to tap fintech: Ashneer
- AAP major beneficiary of proceeds of crime, ED tells SC
- India aims for $1-trn goods export by 2030
- Swiggy to raise $1.2 bn via IPO
- Salesforce takes up CSR activity
- Vodafone Idea raises Rs 18K cr
- Mkts rise for fifth day in a row on banking, metal stocks surge
- HC directs MLA disqualification pleas to be sent to Speaker, adjourns hearing to April 29
- Biju Menon set to give a re-entry into Tamil cinema after 14 years
Just In
Aurobindo Pharma Q4 net up at Rs 801.18 crore
Drug firm Aurobindo Pharma on Monday reported a consolidated net profit of Rs 801.18 crore for the fourth quarter ended March 2021
New Delhi: Drug firm Aurobindo Pharma on Monday reported a consolidated net profit of Rs 801.18 crore for the fourth quarter ended March 2021. The company had posted a net profit of Rs 863.16 crore for the corresponding period of the previous fiscal, Aurobindo Pharma said in a regulatory filing. Its consolidated revenue from operations stood at Rs 6,001.50 crore for the quarter under consideration. It was Rs 6,158.43 crore a year ago, it added. "Net profit after JV share, minority interest is not comparable due to Natrol divestment," Aurobindo Pharma said.
For the fiscal ended March this year, the company posted a net profit of Rs 5,333.83 crore. It was Rs 2,843.67 crore in the preceding fiscal year, the filing said. The company's revenue from operations stood at Rs 24,774.63 crore for 2020-21. It was Rs 23,098.50 crore in the previous fiscal, it added. "We are pleased to have ended the fiscal year with steady growth across our key businesses in a dynamic environment affected by the pandemic," Aurobindo Pharma MD N Govindarajan said.
The company made good progress on its pipeline efforts to focus more on differentiated and complex generic opportunities and reached important milestones in the journey during the year, he added. The company's board has also approved the transfer of all equity shares held in Aura Cure Pvt Ltd, a wholly-owned subsidiary of the company, to Eugia Pharma Specialities Limited, another wholly-owned subsidiary of the company, the filing said. The board has also approved the transfer of business undertaking comprised in Unit-16 of the company on a going concern basis to Wytells Pharma Pvt Ltd, a wholly-owned step-down subsidiary of the company, it added. Shares of Aurobindo Pharma were trading at Rs 992.75 per scrip on BSE, down 2.85 per cent from its previous close.
© 2024 Hyderabad Media House Limited/The Hans India. All rights reserved. Powered by hocalwire.com